Biotech | January 22, 2022
Positive top-line results for bimekizumab in second phase 3 psoriatic arthritis study
UCB plans to submit regulatory applications in Q3 2022
UCB plans to submit regulatory applications in Q3 2022
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
The appointment is key for DefiniGEN as they expand the service portfolio to encompass compound screening
First of its kind integrated Heart Health Programme on its Health Station ‘hPod’
Vigabatrin is an anticonvulsant. It is known to work by stopping the breakdown of a natural calming substance (GABA) in the brain
The company will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
Subscribe To Our Newsletter & Stay Updated
